Bristol-Myers Squibb (BMY) has delivered mixed results for investors lately, with the stock slipping around 23% year-to-date. Despite this, the company’s earnings have shown resilience. This keeps the focus on how its fundamentals stack up.
Bristol-Myers Squibb’s share price has steadily lost ground through 2024, with a year-to-date price return of -23.17%. This points to fading momentum after a tough stretch for pharma stocks. Over the last twelve months, the company has delivered a total shareholder return of -13.94%, signaling that investor sentiment remains cautious despite underlying earnings resilience.
If you’re interested in finding more healthcare stocks with potential, this is a great time to see the full list via our See the full list for free..
With the share price lagging and the stock trading below most analyst targets, investors are now left asking whether this is a genuine value opportunity or if the market is already discounting future growth.
Advertisement
Most Popular Narrative: 17.7% Undervalued
Bristol-Myers Squibb’s fair value narrative places the company’s worth at $53, which is notably above the last close price of $43.63. This sizable gap hints at significant upside if the narrative plays out as outlined by analysts’ key assumptions.
Robust late-stage pipeline and ongoing life-cycle management for major brands, plus strategic partnerships (BioNTech, Philochem, Bain), expand the breadth of future regulatory approvals and label expansions, opening additional indications and helping to offset upcoming patent expiries, which underpins top-line and earnings growth.
Curious which financial levers analysts expect to drive this potential upside? A mix of margin improvement, bold revenue projections, and blockbuster drug launches set the stage for a valuation calculation unlike anything in BMY's recent history. Find out which assumptions are doing the heavy lifting behind that fair value estimate. There is more under the surface than meets the eye.
However, looming patent expiries and tougher drug pricing reforms remain catalysts that could quickly unravel the bullish outlook for Bristol-Myers Squibb.
Looking at valuation through our SWS DCF model gives a strikingly different picture. It suggests Bristol-Myers Squibb could be deeply undervalued, trading far below our estimate of fair value. This gap raises the question: Is the market overlooking longer-term potential while focusing on near-term uncertainties?
If you want to dig deeper or have your own take on Bristol-Myers Squibb’s outlook, you can quickly create and share a personal narrative in just a few minutes. Do it your way
A great starting point for your Bristol-Myers Squibb research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
Looking for More Investment Ideas?
Want to be the first to spot tomorrow’s standout stocks? Don’t wait until everyone else catches on. Unlock unique opportunities with these handpicked lists:
This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Bristol-Myers Squibb might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
